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Abstract
The prevalence of conditions that eventually result in poor wound healing abounds as 
humans advance in age. With the increased possibility of wounds not healing comes 
a leap in morbidity and mortality with its accompanying socioeconomic impact. It is 
therefore relevant to understand what accounts for aberrant wound healing and more 
importantly the molecular markers involved in this pathological state. There are known 
events associated with the wound healing process, spanning from cellular involvement 
to the role of specific proteins such as cytokines and growth factors that are significant 
biomarkers in the wound healing process. This chapter discusses biomarkers relevant 
to the wound healing process, and these biomarkers go a long way to help identify and 
stratify nonhealing patients for whom biomarker-guided approaches may be of impor-
tance clinically in their management.
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1. Introduction
The concept of biomarkers has existed from the time of the inception of ayurvedic medicine, 
just around the seventh century when the sweetness of urine was linked to diabetes even 
though the terminology had not been developed then [1]. The perspective of what constitutes 
the definition of a biomarker is somewhat diverse. Biomarkers (biological markers) are gener-
ally biomolecules whose qualitative and quantitative presence provides an indication of the 
state of a biological system. A more exhaustive definition as provided by the World Health 
Organization (WHO) led joint venture on chemical safety that describes a biomarker as any 
substance, structure, or process that can be measured in the body or its products that can 
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influence or predict the incidence of outcome or disease [2]. The application of biomarkers has 
attained a vital and grounded position in clinical research, usually as predictors of the clinical 
outcomes for a varied number of disease conditions and their management [3].
Extensive scientific investigation into the mechanism of wound healing has revealed that the 
traditional guides in the determination of the wound healing potential, i.e., erythrocyte sedi-
mentation rate (ESR) and C-reactive protein, do not yield enough positive and negative pre-
dictive values [4]. In lieu of the scientific evidence available, the focus has shifted to cytokines, 
chemokines, and proteases which hold the greatest potential as biomarkers [4].
2. Cytokines
Cytokines are proteins of relatively low molecular weight that are secreted to influence or 
modulate the behavior of immune cells and also other cells [5]. Crucial among them include 
interleukins, lymphokines, and other signaling molecules such as interferons and tissue 
necrosis factor (TNF-α). It has been long considered and corroborated by scientific evidence 
that pro-inflammatory cytokines such as interleukins 1α (IL-1α), 1β (IL-1β), and 6 (IL-6) and 
TNF-α play essential roles in wound healing process such as the stimulation of keratinocyte 
and fibroblast proliferation, modulation of immune response, synthesis and breakdown of 
extracellular matrix proteins, and the chemotaxis of fibroblast to the wound site [6].
Grellner et al. [7, 8] in their work to quantitatively analyze pro-inflammatory cytokines in 
human skin wounds realized an upregulation of the expression of IL-1α, IL-1β, IL-6, and 
TNF-α in the inflammatory phase of the wound healing process. The levels of these pro-
inflammatory cytokines (TNF-α, IL-1, and IL-6) were higher in nonhealing wounds than 
healing wounds owing to the fact that nonhealing wounds stay in the inflammatory phase 
of wound healing process [4]. Bilder et al. [9] also report an increase in the levels of IL-8 in 
chronic nonhealing wounds as opposed to those with a healing potential. Ligi et al. [10] upon 
the assessment of several studies which evaluated the level expression of cytokines and che-
mokines in the microenvironment of a chronic ulcer alluded to a heightened pro-inflammatory 
condition in a nonhealing wound, thus corroborating other studies. It was however noted that 
the level of cytokines detectable does not necessarily correlate to its bioactivity due to anti-
inflammatory cytokines whose presence counteracts the activity of these pro-inflammatory 
cytokines [10]. There are also specific cytokine inhibitors and proteolytic enzymes that also 
act on these cytokines to mask their bioavailability [10]. Patel et al. [4] also report the incon-
sistency in wound and serum levels of cytokines which poses a challenge in its use as reliable 
biomarkers of nonhealing wounds.
2.1. Interleukin 1 (IL-1)
The IL-1 family of cytokines is made up of two pro-inflammatory cytokines, namely, IL-α 
and IL-β. Interleukin 1 is primarily sourced from macrophages in the event of injury, infec-
tion, and antigenic challenge although the epidermal, epithelial, lymphoid, and vascular 
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tissues also serve as reservoirs for the polypeptide [11]. The actions of IL-1 span from sys-
temic changes in the neurological, hematologic, endocrinologic, and metabolic systems to 
some local effects that are particularly relevant in wound healing [12]. By influencing both 
destructive and repair processes, it contributes the mesenchymal tissue remodeling, and it 
does so by influencing quite a number of cells. First of all, it stimulates capillary endothelial 
cells to produce chemokines such as MCP-1 and also cause an upregulation of the synthesis of 
vascular adhesion molecules such as ICAM-1, VCAM-1, and E-selectin [13, 14]. The combined 
effect of these two actions is to cause the infiltration of the injury site with mononuclear cells, 
thus setting the stage for inflammatory response. The expression of matrix metalloproteases 
(MMPs) from resident fibroblasts is also under the control of IL-1. The call of MMPs to play 
results in the degradation of the extracellular matrix to allow for enhanced monocyte migra-
tion. It also leads to a down-modulation of the inflammatory response as MMPs degrade IL-1. 
Inhibiting the IL-1 pathway through the use of recombinant antibodies and macrophages 
from IL-1 receptor knockout mice appeared to turn the tables around as far as the wound 
microenvironment is concerned by inducing a switch from pro-inflammatory to healing-
associated macrophage phenotypes and growth factors [14]. Therefore, there is a negative 
implication for wound healing in the absence of high expression of IL-1.
2.2. Interleukin 6 (IL-6)
Interleukin 6 is described as the chief contributor to the stimulation of a majority of the 
acute-phase proteins during inflammation. IL-6-deficient transgenic mice (IL-6 KO) therefore 
showed a substantial delayed cutaneous wound healing relative to the wild-type control ani-
mals by about threefold, the time required for healing [15].
Based on similar animal model studies on IL-6 knockout mice and the administration of 
recombinant murine IL-6 protein, IL-6 was found to be essential in stimulating the mitogenic 
activity of keratinocytes, an action that has been linked to scar formation as well as exerting 
a chemo-attractive action on neutrophils [6]. These effects seek to kick-start the wound heal-
ing process. However, a study conducted to determine the indicators of inflammation in the 
pathogenesis of diabetic foot ulcers identified a positive correlation between high serum IL-6 
levels in diabetic patients with foot ulcers and low serum IL-6 levels in those without foot 
ulcers. This implicates its effect on poor wound healing [16].
This is not surprising as IL-6 has a reputation for dictating the transition from acute to chronic 
inflammation systemically by its stimulatory effects on T and B cells.
2.3. Tumor necrosis factor-α (TNF-α)
Tumor necrosis factor alpha (TNF-α) is a key pro-inflammatory cytokine involved in the early 
phase of most inflammatory events in the body. Employing mouse models, the expression 
of TNF-α at detectable levels was discovered to happen just after wound creation and sees 
an increase in the first several hours until it reaches a peak within 24 hours after which it 
returns to the basal level [17]. Vascular endothelial cells, keratinocytes, and fibroblasts are the 
major sources of TNF-α which cause an initiation of the inflammatory phase of the wound 
Biomarkers of Wound Healing
http://dx.doi.org/10.5772/intechopen.80222
25
healing by promoting the recruitment of inflammatory leukocytes. TNF-α is also involved in 
the regulation of the activity of fibroblasts, keratinocytes, and vascular endothelial cells as 
well as in modulating synthesis of extracellular matrix proteins and matrix metalloproteinase 
[17, 18]. Based on diabetic models, an increase in TNF-α level coupled with decrease in IL-10 
that has anti-inflammatory properties results in sustained expression of chemokines CXCL2 
and CCL2 and leads to continuous infiltration of leucocytes to the injury site. This ultimately 
prolongs the inflammation and reduces the wound healing potential [19].
2.4. Transforming growth factor (TGF)
Transforming growth factor describes the superfamily for pluripotent cytokines which have 
very important functions to perform during disease, homeostasis, development, and repair. 
These sets of proteins are structurally related, but functionally distinguishable and relevant 
among them for wound healing are the isoforms TGF-β 1–3 [20]. The roles of these isoforms 
in the wound healing process can be both distinct and overlapping. However, the overall 
nature of their contribution to the wound healing has generated some controversy and thus 
is among the most studied molecules involved in the process [6]. Transforming growth factor 
β1 (TNF-β1) however has the widest spectrum of actions, affecting all manners of cell types 
that are involved in all stages of wound healing. These effects have been reported to be both 
positive and negative [21]. Historically, the synthesis of TNF-β1 from keratinocytes, platelets, 
and macrophages is upregulated right after injury, and this is crucial for initiating inflam-
mation and granulation tissue formation. In addition, TNF-β1 contributes to the chemotactic 
migration of cells during wound repair. Some proteases such as MMP-1, MMP-2, MMP-3, 
and MMP-9 are also under the control of TNF-β1 [6, 22]. Based on human studies, TNF-β1 
was found to stimulate the production of extracellular matrix molecules, including collagens 
and fibronectin, which strengthen the repaired wound. In spite of this knowledge, available 
evidence goes to raise questions about the true effects of TNF-β1 levels on wound healing 
[23]. Wound healing in Smad knockout mice, which have the signaling pathway of TNF-β1 
blocked, was rather accelerated to the surprise of the investigators. In similar fashion, TNF-β1 
knockout mice showed demonstrated reepithelialization during incisional wound repair, in 
comparison with wild-type mice. The consensus in the face of current evidence is that the 
selective inhibition of TNF-β1 in some cells may prove beneficial [24].
3. Growth factors
The growth factors are essentially responsible for the initiation of the proliferation stage of the 
wound healing process. The platelet-derived growth factor (PDGF), transforming growth fac-
tors (TGF-𝛼, TGF-𝛽), insulin growth factor (IGF-1), fibroblast growth factor (FGF), and gran-
ulocyte-macrophage colony-stimulating factors (GM-CSF) are examples of growth factors 
whose roles in wound healing as well as their possible use as biomarkers have been studied 
extensively based on their expressed levels [25]. In spite of the fact that insight about ideal lev-
els and the spatiotemporal distribution of growth factors is far from complete, available data 
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points to no local growth factor deficiency in chronic leg ulcers with the possible exception of 
TGF [6]. Trengove et al. [26] after studying wound fluids from both healing and nonhealing 
wounds arrive at similar conclusion that poor wound healing may be due to inflammatory 
mediators rather than a deficiency of growth factors.
3.1. Platelet-derived growth factors (PDGF)
Platelet-derived growth factors (PDGFs) are made up of a family of homodimeric or heterodi-
meric growth factors, including PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD 
[27]. PDGF has been established to have chemotactic role for cells that migrate to the heal-
ing wound site such as fibroblasts, neutrophils, and monocytes. It was actually the very first 
growth factor shown to have this function [28]. It additionally stimulates the proliferation of 
fibroblast and the deposition of extracellular matrix. In vitro studies have also revealed that 
it stimulates insulin growth factor (IGF) release in fibroblasts which is vital to the initiation 
of the repair process [28]. Lastly, it stimulates fibroblasts to contract collagen matrices and 
induces the myofibroblast phenotype in the implicated cells. It has thus been established to 
be a major player in the wound healing and has formed the basis for studies into its clinical 
application in the treatment of wound healing disorders.
Owing to the close proximity of the expression sites of the PDGF, which is predominantly 
in the epidermis, and its receptors which are also in the dermis and granulating tissue, a 
paracrine mechanism has been suggested for its action [6, 29]. However, unlike other growth 
factors like fibroblast growth factor (FGF) and vascular epithelial growth factor (VEGF) that 
see an overexpression in the microenvironment or at the site of a healing wound or one in a 
granulation phase, the increase in the expression of PDGF-BB is without this spatial limitation 
as its levels in plasma also increases. It does make it potentially useful as the biomarker in 
wound healing [10].
4. Proteases
The action of proteases and their inhibitors goes a long way to influence the equilibrium 
between extracellular matrix (ECM) degradation and deposition which is responsible for the 
coordinated and timely healing of wounds [30]. There is an overwhelming wealth of evidence 
to suggest that nonhealing wounds are characterized by an increase in the levels of proteases 
and an imbalance in the protease/protease inhibitor levels [30, 31]. This manifests as a per-
sistence of proteolysis and degradation of the extracellular matrix causing wound healing to 
delay. Significant among these proteases are the matrix metalloproteases (MMPs) [32]. MMPs 
are part of a family of zinc endopeptidase which essentially help in the degradation of pro-
visional extracellular matrix, facilitate the migration of inflammatory cells to the wound site, 
remodel the granulation tissue, and modulate angiogenesis [28]. MMP activity as measured 
using Azocoll assay was found to be significantly elevated in chronic wounds as compared to 
acute wounds, thus implicating it poor wound healing [26].
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Proteases as biomarkers for wound healing hold the key to transform clinical approach to 
the management of wounds. For example, the appropriateness of using protease-modulating 
dressing and tissue-engineered products, scaffolds, and skin grafts for the treatment can be 
made by the determination of the levels of proteases [33].
5. Matrix metalloproteinase
Matrix metalloproteinases (MMPs) are a group of endopeptidase that are zinc and calcium 
dependent and are usually divided into six groups depending on the substrate they act on. 
These MMPs consist of collagenases (MMP-1, MMP-3, MMP-8); gelatinases (MMP-2, MMP-9); 
stromelysins (MMP-3, MMP-10); matrilysins (MMP-7, MMP-26); membrane-type MMPs 
(MT-MMP) like MMP-14, MMP-15, MMP-16, and MMP-24; and other MMPs (MMP-11, 
MMP-12, MMP-19, MMP-20, MMP-22, MMP-23, MMP-28) [34].
Various MMPs are relevant to the wound healing process at varied points, and the tight con-
trol of their proteolytic activity is also essential to conduct the different events of wound 
healing [36]. MMPs are however generally involved in the inflammatory, proliferative, and 
remodeling phases of the wound healing process by modulating cytokine/chemokine activity 
by activating them enzymatically or influencing their availability by cleaving them from cell 
surface. Additionally, the actions of MMPs involve the breakdown of proteins part of the cell-
cell and cell-extracellular matrix interaction [35, 36].
In terms of the predictive roles of MMPs’ level for the wound healing process, some stud-
ies have focused on the MMP-1 to tissue inhibitor of metalloproteinase (TIMP-1) ratio. In 
one study, for instance, a significant correlation was found between a high ratio of MMP-1/
TIMP-1 and good healing (r = 0.65, p = 0.008) with receiver operator curve (ROC) analysis 
showing an MMP-1/TIMP-1 ratio of 0.39 being the best predictive value for wound healing. 
High levels of MMP-8 and MMP-9 also appear to have negative predictive value for the pro-
cess of wound healing [32].
6. Conclusion
With the growing research into the therapeutic benefits of biomarkers comes the challenge of 
identifying biomarkers that satisfy the required characteristics for use clinically. It is prudent 
to validate new biomarkers affecting the wound healing process by employing innovative, 
simple, and cost-effective molecular approaches to determine the type, level, and activity 
of all potential biomarkers. With the advent of trendsetting technical knowhow in defining 
diseases and other biological processes, it has become increasingly possible to identify and 
characterize novel biomarkers of the wound healing process. Continuing the research into 
identification of new biomarkers affecting the wound healing process is imperative since it 
will eventually have weighty health benefits on patients and offer a relevant guide to wound 
management. This will significantly lower the risks of microbial colonization and invasion of 
wounds and loss of structural function as a result of chronic wounds.
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